Status:
COMPLETED
Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Critical Illness
Kidney Injury
Eligibility:
All Genders
18+ years
Brief Summary
Severe acute kidney injury (AKI) is a common complication of critical illness affecting almost half of all patients with septic shock. Extracorporeal renal replacement therapy is a cornerstone in the ...
Eligibility Criteria
Inclusion
- Critically ill adults \[age ≥ 18\] admitted to one of two of the medical/surgical intensive care units (ICUs) of The Ottawa Hospital, who require SLED and are or will receive meropenem, piperacillin-tazobactam or vancomycin therapy at any dose.
Exclusion
- Patients for whom participation via the informed consent process is denied.
- Critically ill patients with a hypermetabolic state due to \>25% coverage of body surface area burn, cystic fibrosis, spinal cord injury, bariatric patients (defined as \>150kg total body weight)
- Patient is pregnant as per a positive serum or urine βHCG qualitative assay
- Patient does not have a closed-system arterial or central venous catheter (to minimize blood wastage)
- Patients receiving concomitant drugs known to interact with the metabolism or clearance of the antimicrobial of interest according to Micromedex 2.0 (Truven Health Analytics Inc 2013)
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT02242006
Start Date
October 1 2014
End Date
March 1 2016
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6